4β-hydroxycholesterol as a marker of CYP3A4 inhibition in vivo - Effects of itraconazole in man

International Journal of Clinical Pharmacology and Therapeutics

Volumn 47, Issue 12, 2009, Pages 709-715

  Lutjohann D ^a   Marinova, M ^a   Schneider, B ^a   Oldenburg, J ^a   von Bergmann, K ^a   Bieber, T ^a   Bjorkhem I ^b   Diczfalusy, U ^b  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Azoles; Biomarker; Cytochrome P450; Lanosterol; Oxysterols

Indexed keywords

26 HYDROXYCHOLESTEROL; 7ALPHA HYDROXYCHOLESTEROL; BILE ACID; CHOLESTEROL; CYTOCHROME P450 3A4; DESMOSTEROL; DIHYDROLANOSTEROL; FENOFIBRATE; ITRACONAZOLE; LATHOSTEROL; OXYSTEROL; ANTIFUNGAL AGENT; CHOLEST 5 ENE 3,4 DIOL; CHOLEST-5-ENE-3,4-DIOL; CHOLESTEROL DERIVATIVE; CYP3A4 PROTEIN, HUMAN; CYTOCHROME P450 3A; PHARMACOLOGICAL BIOMARKER;

ARTICLE; BLOOD SAMPLING; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; CLINICAL ARTICLE; CLINICAL TRIAL; ENZYME INHIBITION; ENZYME METABOLISM; FLAME PHOTOMETRY; GAS CHROMATOGRAPHY; HUMAN; IN VIVO STUDY; MALE; MASS FRAGMENTOGRAPHY; MORNING DOSAGE; MULTIPLE CYCLE TREATMENT; ONYCHOMYCOSIS; BLOOD; DRUG ANTAGONISM; METABOLISM;

ANTIFUNGAL AGENTS; BIOMARKERS, PHARMACOLOGICAL; CHOLESTEROL; CYTOCHROME P-450 CYP3A; HUMANS; HYDROXYCHOLESTEROLS; ITRACONAZOLE; MALE; ONYCHOMYCOSIS;

EID: 71849114209     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP47709     Document Type: Article

References (24)

1. Björkhem I, Diczfalusy U. Oxysterols: friends, foes, or just fellow passengers? Arterioscler Thromb Vasc Biol. 2002; 22: 734-742.
2. Bodin K, Bretillon L, Aden Y, Bertilsson L, Broome U, Einarsson C, Diczfalusy U. Antiepileptic drugs increase plasma levels of 4β-hydroxycholesterol in humans: evidence for involvement of cytochrome p450 3A4. J Biol Chem. 2001; 276: 38685-38689.
3. Bodin K, Andersson U, Rystedt E, Ellis E, Norlin M, Pikuleva I, Eggertsen G, Björkhem I, Diczfalusy U. Metabolism of 4β-hydroxycholesterol in humans. J Biol Chem. 2002; 277: 31534-31540.
4. Diczfalusy U, Kanebratt KP, Bredberg E, Andersson TB, Bottiger Y, Bertilsson L. 4β-hydroxycholesterol as an endogenous marker for CYP3A4/5 activity. Stability and half-life of elimination after induction with rifampicin. Br J Clin Pharmacol. 2009; 67: 38-43.
5. Diczfalusy U, Miura J, Roh HK, Mirghani RA, Sayi L, Larsson H, Bodin KG, Allquist A, Jande M, Kim JW, Aklillu E, Gustafsson LL, Bertilsson L. 4β-Hydroxycholesterol is a new endogenous CYP3A marker-relationship to CYP3A5 genotype, quinine 3-hydroxylation and gender in Koreans, Swedes and Tanzanians. Pharmacogenet Genom. 2008; 18: 201-208.
6. Eichelbaum M, Burk O. CYP3A genetics in drug metabolism. Nat Med. 2001; 7: 285-287
7. Galteau MM, Shamsa F. Urinary 6β-hydroxycortisol: a validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals. Eur J Clin Pharmacol. 2003; 59: 713-733.
8. Gylling H, Vanhanen H, Miettinen TA. Effects of ketoconazole on cholesterol precursors and low density lipoprotein kinetics in hypercholesterolemia. J Lipid Res. 1993; 34: 59-67
9. Gylling H, Vanhanen H, Miettinen TA. Hypolipidemic effect and mechanism of ketoconazole without and with cholestyramine in familial hypercholesterolemia. Metabolism. 1991; 40: 35-41.
10. Kajosaari LI, Laitila J, Neuvonen PJ, Backman JT. Metabolism of Repaglinide by CYP2C8 and CYP3A4 in vitro. Basic Clin Pharmacol Toxicol. 2005; 97: 249-256.
11. Kempen HJ, Glatz JF, Gevers Leuven JA, van der Voort HA, Katan MB. Serum lathosterol concentration is an indicator of whole-body cholesterol synthesis in humans. J Lipid Res. 1988; 29: 1149-1155.
12. Knabe C, Sudhop T, von Bergmann K, Lütjohann D. Degradation of 24S-hydroxycholesterol in men is not regulated by CYP7A1. Int J Clin Pharmacol Ther. 2007; 45: 577-582.
13. Lepesheva GI, Waterman MR. Sterol 14α-demethylase cytochrome P450 (CYP51), a P450 in all biological kingdoms. Biochim Biophys Acta. 2007; 1770: 467-477.
14. Lütjohann D, Brzezinka A, Barth E, Abramowski D, Staufenbiel M, von Bergmann K, Beyreuther K, Multhaup G, Bayer TA. Profile of cholesterol-related sterols in aged amyloid precursor protein transgenic mouse brain. J Lipid Res. 2002; 43: 1078-1085.
15. Marschall HU, Wagner M, Zollner G, Fickert P, Diczfalusy U, Gumhold J, Silbert D, Fuchsbichler A, Benthin L, Grundstrom R, Gustafsson U, Sahlin S, Einarsson C, Trauner M. Complementary stimulation of hepatobiliary transport and detoxification systems by rifampicin and ursodeoxycholic acid in humans. Gastroenterology. 2005; 129: 476-485.
16. Mirghani RA, Ericsson O, Tybring G, Gustafsson LL, Bertilsson L. Quinine 3-hydroxylation as a biomarker reaction for the activity of CYP3A4 in man. Eur J Clin Pharmacol. 2003; 59: 23-28.
17. Pierard GE, Arrese JE, Pierard-Franchimont C. Itraconazole. Exp Opin Pharmacother. 2000; 1: 287-304.
18. Rogers JF, Rocci ML Jr., Haughey DB, Bertino JS, Jr. An evaluation of the suitability of intravenous midazolam as an in vivo marker for hepatic cytochrome P4503A activity. Clin Pharmacol Ther. 2003; 73: 153-158.
19. Schneider B, Gerdsen R, Plat J, Dullens S, Björkhem I, Diczfalusy U, Neuvonen PJ, Bieber T, von Bergmann K, Lütjohann D. Effects of high-dose itraconazole treatment on lipoproteins in men. Int J Clin Pharmacol Ther. 2007; 45: 377-384.
20. Shafaati M, Mast N, Beck O, Nayef R, Heo GY, Björkhem-Bergman L, Lütjohann D, Björkhem I, Pikuleva A. The antifungal drug voriconazole is an efficient inhibitor of brain cholesterol 24S-hydroxylase (CAP46A1) in vitro and in vivo. J Lipid Res. 2009; May 27 (Epub ahead of print).
21. Svecova L, Vrzal R, Burysek L, Anzenbacherova E, Cerveny L, Grim J, Trejtnar F, Kunes J, Pour M, Staud F, Anzenbacher P, Dvorak Z, Pavek P. Azole antimycotics differentially affect rifampicin-induced pregnane X receptor-mediated CYP3A4 gene expression. Drug Metab Dispos. 2008; 36: 339-348.
22. Tomalic-Scharte D, Lütjohann D, Doroshyenko O, Frank D, Jetter A, Fuhr U. Plasma 4β-Hydroxycholesterol: An endogenous CYP3A Metric? Clin Pharmacol Ther. 2009; doi:10.1038/clpt.2009.72:1-7.
23. Vanden Bossche H, Willemsens G, Marichal P. Anti-Candida drugs - the biochemical basis for their activity. Crit Rev Microbiol. 1987; 15: 57-72.
24. Wide K, Larsson H, Bertilsson L, Diczfalusy U. Time course of the increase in 4β-hydroxycholesterol concentration during carbamazepine treatment of pediatric patients with epilepsy. Br J Clin Pharmacol. 2008; 65: 708-715.